61367-24-6

Basic information

• Product Name: (4-{[(2-chloroethyl)carbamoyl]amino}cyclohexyl)acetic acid
• CAS NO: 61367-24-6
• Molecular Formula: C₁₁H₁₉ClN₂O₃
• Molecular Weight: 262.7332
• Mol File: 61367-24-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 514.9°C at 760 mmHg
• Flash Point: 265.2°C
• Density: 1.24g/cm³
• Vapor Pressure: 5.44E-12mmHg at 25°C
• Refractive Index: 1.524
• CAS DataBase Reference: (4-{[(2-chloroethyl)carbamoyl]amino}cyclohexyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (4-{[(2-chloroethyl)carbamoyl]amino}cyclohexyl)acetic acid(61367-24-6)
• EPA Substance Registry System: (4-{[(2-chloroethyl)carbamoyl]amino}cyclohexyl)acetic acid(61367-24-6)

Safety Data

• Hazardous Substances Data: 61367-24-6(Hazardous Substances Data)

Usage

General Description

The chemical (4-{[(2-chloroethyl)carbamoyl]amino}cyclohexyl)acetic acid, also known as cyclophosphamide, is a synthetic alkylating agent used in chemotherapy to treat various types of cancer. It works by interfering with the growth and spread of cancer cells in the body and is particularly effective against lymphoma, multiple myeloma, and certain types of leukemia. Cyclophosphamide is able to cross-link DNA, which ultimately leads to cell death and suppression of the immune system. It can be administered orally, intravenously, or intramuscularly and is often used in combination with other chemotherapy medications. Common side effects include nausea, vomiting, hair loss, and increased susceptibility to infections.

Upstream product

• 1943-83-5 2-chloroethyl isothiocyanate 
• 2952-00-3 trans-2-(4-aminocyclohexyl)acetic acid 
• 2901-44-2 trans-2-(4-acetamidocyclohexyl)acetic acid 

Downstream Products

• 52320-89-5 C₁₁H₁₈ClN₃O₄ 

Relevant articles and documents

Synthesis of analogues of N (2 chloroethyl) N' trans 4 methylcyclohexyl) N nitrosourea for evaluation as anticancer agents

The superior activity of N (2 chloroethyl) N' (trans 4 methylcyclohexyl) N nitrosourea (MeCCNU) against advanced murine Lewis lung carcinoma in comparisons with the cis form and other nitrosoureas prompted the synthesis of a number of MeCCNU analogues, including several cis trans pairs. The methyl group was replaced by a variety of substituents (CO2H, CH2CO2H, CO2Me, CH2OAc, CH2Cl, OMe); the trans 3 methylcyclohexyl, cis 2 methyl 1,3 dithian 5 yl, cis and trans 2 methyl 1,3 dithian 5 yl tetraoxide, and 1 methylhexyl (open chain) analogues were also prepared. Preliminary tests against murine leukemia L1210 revealed therapeutic indices (ED50/LD10) ranging from 0.26 to 0.79; all but 3 analogues effected 50% cure rates at nontoxic doses, the open chain analogue being one of the least active. In terms of therapeutic index, diequatorial (trans 4) isomers were, with one exception, as active as or, in 4 of the 8 examples, somewhat more active than the corresponding axial equatorial (cis 4) isomers. In this series, 4 of the 5 2-fluoroethyl analogues prepared were clearly inferior to the corresponding 2 chloroethyl analogues.